Wyeth third quarter
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Consumer Healthcare's recent divestiture of theSolgar supplement business contributed to a 4.7% dip in domestic revenues for the third quarter, the firm reported during an earnings call Oct. 21.Wyeth closed the sale of its Solgar business to NBTY for $115 mil. on Aug. 1. Domestic sales for the division during the quarter closed at $382.5 mil., down from $401.5 mil. during the third quarter of 2004. Losses due to Solgar were partially offset by gains in worldwide Centrum revenues, up 14% to $150 mil. for the third quarter, the company said. Growth during the first nine months for the division was driven by a global increase in Robitussin, Caltrate and Advil sales. When excluding the impact of foreign exchange, total worldwide consumer net revenue decreased by 4% for the third quarter, Wyeth stated...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.